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RESULTS
• Zika virus (ZIKV): mosquito-borne flavivirus
o Since 2015: transmission detected in more than 80 countries
o Zika congenital syndrome (ZCS): microcephaly and several other
fetal malformations (from ~ 42% of infected mothers, Brasil et al.,
2016)
o Also linked to autoimmune neurological syndrome in adults
(Guillain-Barré Syndrome)
• Need for Zika vaccine: to avoid future periodic outbreaks in
endemic areas or future spread to currently non-endemic
regions
• Virus-like particles: 3D structures that mimick the virus, made
of recombinant structural proteins of the virus, but lacking
the viral genome
o Epitopes displayed in repeated regular pattern: effective
immunogens for vaccines
• Perfusion processes: higher volumetric productivities,
reduced bioreactor sizes, less plant footprint and lower




Fig. 1: Development of a HEK293 stable cell pool producing Zika VLPs and its 
cultivation in perfusion mode. All steps since host cell line maintenance and 
transfection were carried out in animal component free medium.
• Cell line development
o Transfection to produce structural pre-membrane (prM) and
envelope (E) ZIKV proteins (GenBank # KU365779)
o HEK293SF-3F6 cell line (NRC, Canada) cultivated in HEK TF
medium (Xell AG, Germany)
o Enrichment of stable cell pools producing Zika VLPs by FACS
(Fluorescence Activated Cell Sorting)
• Process development
o Kinetic studies in shake flasks: batch and pseudoperfusion
evaluation (intermittent medium exchange): definition of
optimal feeding strategy in shaken tubes
o Perfusion cultivation in stirred-tank bioreactor (ez-Control,
Applikon Biotechnology, The Netherlands) coupled to XCell™
ATF-2 (Repligen, USA) as cell retention device. Working volume


















• Stable cell lines producing VLPs: enables the development of a continuous production platform that could potentially lead to
an affordable vaccine to be manufactured in low biosafety level facilities;
• Intermittent (PP) or continuous perfusion medium exchange led to a 3-fold increase in maximum VCD and 4-fold increase in
maximum product titer;
• Perspectives for the near future: use of a CHO-K1 cell line constitutively producing ZIKV VLPs – robustness and lower media
costs.
Fig. 2: Production of Zika VLPs under different modes of 
operation. Viable cell density (VCD) and viability (A) and VLP 
concentration and medium exchange rate shown for cells 
cultivated in shaken tubes, under batch and pseudoperfusion
(PP) modes of operation. (C) Confirmation of the increase in 
VLP production after cell sorting and stability production 
over time. (D) and (E) show results for cells cultivated in 
perfusion mode in stirred-tank bioreactor. 
Table 1: Maximum VCD, product titer and volumetric 
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AIM
Production of Zika virus-like particles (VLPs) in perfusion mode,
enabled by the development of cell pools showing stable and
constitutive expression, was investigated with the aim of
developing a more cost-effective technology for vaccine




Parameter Batch PP Perfusion
𝑽𝑪𝑫𝐦𝐚𝐱 (× 𝟏𝟎
𝟔 𝐜𝐞𝐥𝐥𝐬/𝐦𝐋) 11.3 ± 0.8 37.4 ± 0.2 30.7 ± 0.4
𝐏𝐦𝐚𝐱 (µg/mL) 21.9 ± 1.8 89.1 ± 1.9 91.3 ± 11.2
𝐏𝐯 (mg/L/d) 3.4 22.4 25.0
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